|
|
|
|
| Join Drug Delivery Leader Live in discussing human factors risk analysis approaches for combination products and medical devices. Central to the conversation will be the FDA’s draft guidance on Use-Related Risk Analysis (URRA) and how this guidance is related to other risk tools, such as a use Failure Mode and Effects Analysis (uFMEA). Secure your spot for this free digital event happening November 13th. |
|
|
|
|
By Jeff Cohen, American IV Association and Florida Healthcare Law Firm | The regulatory environment surrounding IV therapy and med spas has become fragmented. In some states, the definition of compounding has been expanded. |
|
|
|
| Is My Molecule Suitable For An Orally Disintegrating Tablet? | White Paper | By Susan Banbury, Ph.D., Adina Dîrlea, Charli Smardon, and Simon A. Lawton, MD, Catalent | Innovations in drug delivery formats are enabling more patient-centric treatments and helping to boost patient compliance. Learn about the advances being developed to expand ODT technology. |
|
|
|
|
|
|
| Spray Drying For Improved Solubility | Q&A | Lonza | Gain expert insights into how to develop a spray dried powder formulation and scale it from early feasibility studies to commercial manufacturing. |
|
|
|
|
|
|
|
.png){kind=logo}
